Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion

BARCELONA, SPAIN - For companies looking to adopt adaptive trial designs, Merck VP of Biostatistics and Research Decision Sciences Jerald Schindler urged sponsors to frontload most of the adaptation in the non-pivotal portion of the clinical trial program and limit their own involvement in the adaptation that does take place during the pivotal portion